Breaking News Instant updates and real-time market news.

REGN

Regeneron

$392.25

-5.38 (-1.35%)

, SNY

Sanofi

$43.82

-0.57 (-1.28%)

08:55
09/15/18
09/15
08:55
09/15/18
08:55

Regeneron says Dupixent showed 'significant improvement' in atopic dermatitis

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented detailed results from a pivotal Phase 3 trial showing Dupixent monotherapy demonstrated a "significant improvement" in signs and symptoms of atopic dermatitis and certain quality of life measures in adolescent patients with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable. These data were presented at the 27th European Academy of Dermatology and Venereology Congress in Paris, France. The co-primary endpoint outside of the U.S. was 75% improvement in Eczema Area and Severity Index at 16 weeks. In the U.S., the primary endpoint was the proportion of patients achieving Investigator's Global Assessment score of 0 or 1.41.5% of patients who received Dupixent every two weeks and 38% of patients who received Dupixent every four weeks achieved 75% or greater skin improvement compared to 8% with placebo; 24% of patients who received weight-based dosing of Dupixent every two weeks and 18% of patients who received a fixed dose of Dupixent every four weeks achieved the primary endpoint - clear or almost-clear skin - compared with 2% with placebo. With regard to key secondary endpoints at 16 weeks, there was a 66% improvement in the Dupixent every two weeks group and 65% improvement in the Dupixent every four weeks group in average percent change from baseline in EASI score compared with a 24% improvement in the placebo group. And there was a 48% improvement in the Dupixent every two weeks group and 45.5% improvement in the Dupixent every four weeks group in average percent change from baseline in the pruritus numerical rating scale compared with a 19% improvement in the placebo group. The overall rate of adverse events was 72% for Dupixent every two weeks, 64% for Dupixent every four weeks and 69% for placebo. Adverse events that were observed more frequently with Dupixent included injection site reactions and conjunctivitis. Skin infections were numerically lower in the Dupixent groups.

REGN

Regeneron

$392.25

-5.38 (-1.35%)

SNY

Sanofi

$43.82

-0.57 (-1.28%)

  • 15

    Sep

  • 27

    Sep

  • 20

    Oct

  • 28

    Oct

  • 29

    Oct

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

  • 13

    May

REGN Regeneron
$392.25

-5.38 (-1.35%)

08/08/18
PIPR
08/08/18
NO CHANGE
PIPR
Overweight
Piper says CMS Part B headlines 'scary,' but Regeneron pullback an overreaction
Piper Jaffray analyst Christopher Raymond said he would be a buyer on weakness in shares of Regeneron after CMS announced new rules giving Medicare Advantage plans the option of implementing "step therapy" to introduce competition. He checked in with leading drug pricing and reimbursement experts, whose view is that this may drive discounting and competition between Eylea and Lucentis, much like what exists today with private pay plans. After speaking with management, Raymond estimates about 3.4% of 2019 Eylea revenue is at risk. Assuming Regeneron has to price at Eylea at a 30% discount translates to a roughly $40M revenue impact and a 36c, or 1.5%, hit to EPS in 2019, said Raymond, who called the 6% pullback in the stock an overreaction in light of those estimates. He maintains an Overweight rating on Regeneron shares.
08/13/18
PIPR
08/13/18
NO CHANGE
PIPR
Overweight
Regeneron should be bought on 'largely meaningless' CRL, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond recommends buying shares of Regeneron Pharmaceuticals on weakness after the company received a Complete Response Letter from the FDA regarding Eylea's supplemental Biologics License Application for Q12W dosing in wet macular degeneration. The CRL is "largely meaningless" as this label expansion is almost entirely a defensive move by Regeneron to counter potential Q12W labeling by competitor Novartis' (NVS) RTH258, Raymond tells investors in a research note. The analyst has "reasonable confidence" that approval for this label will come within two months. He keeps an Overweight rating on shares of Regeneron.
08/16/18
PIPR
08/16/18
NO CHANGE
Target $450
PIPR
Overweight
Regeneron's fasinumab safety remains 'open question,' says Piper Jaffray
Piper Jaffray analyst Christopher Raymond backed an Overweight rating on Regeneron Pharmaceuticals (REGN) shares following this morning's release of fasinumab results, saying the drug and partner Teva's (TEVA) anti-NGF antibody met its primary and secondary efficacy pain and functional endpoints in a Phase 3 trial of patients with chronic pain from osteoarthritis of the knee or hip. Raymond says the efficacy "was never really in doubt," but the bigger focus for the drug is safety, and will wait for detailed data at an upcoming medical meeting, but notes that fasinumab's arthropathy rate appears "slightly higher" than that of tanezumab. Given the severity of the ongoing opioid epidemic and relative lack of alternatives for these patients outside of total joint replacement, the analyst thinks the appetite of regulators and potential market for new effective, non-opioid chronic pain therapies like anti-NGF clearly exists, though he will leave this as an unmodeled potential source of upside for now,
09/13/18
STFL
09/13/18
INITIATION
Target $127
STFL
Buy
AnaptysBio resumed with a Buy at Stifel
Stifel analyst Derek Archila resumed coverage of AnaptysBio (ANAB) with a Buy rating and $127 price target, stating that he is positively biased heading into etokimab's Phase 2a results for severe eosinophilic asthma, given his view on the strong rationale for the inhibition of IL-33, etokimab's meaningful reduction of eosinophils seen in an earlier Phase 2a study, and the success of Regeneron (REGN) and Sanofi's (SNY) Dupixent.
SNY Sanofi
$43.82

-0.57 (-1.28%)

09/10/18
MSCO
09/10/18
INITIATION
Target $72
MSCO
Overweight
MyoKardia initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Jeffrey Hung initiated MyoKardia (MYOK) at Overweight with a $72 price target, stating that the obstructive hypertrophic cardiomyopathy Phase 2 data for its lead program, mavacamten, were "robust" and the fact that the company is partnered with Sanofi (SNY) gives him incremental confidence. He expects a mavacamten launch in oHCM in early 2022 and peak U.S. sales for the drug of greater than $1.3B.
09/10/18
BOFA
09/10/18
UPGRADE
BOFA
Buy
Sanofi upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Graham Parry upgraded Sanofi to Buy from Neutral saying the company is approaching an inflection in growth from new products, mainly Dupixent, atopic, dermatitis, while diabetes becomes less of a headwind. Parry believes sales and earnings growth will accelerate to 7% from 4% in through 20-2023E and views valuation as undervaluing growth.
09/14/18
LSCM
09/14/18
NO CHANGE
Target $90
LSCM
Buy
Apple Watch more likely a positive for BioTelemetry, says Lake Street
After spending time with Joe Capper and Heather Getz, CEO and CFO of BioTelemetry (BEAT), Lake Street analyst Brooks O'Neil senses that Apple's (AAPL) Watch Series 4, which includes a built-in electrocardiogram, is more likely a positive for BioTelemetry "than a buzzer sounding a flat-line for the company's future." BioTelemetry remains the leading cardiac monitoring company and this is likely to continue for the foreseeable future, O'Neil tells investors in a research note. He points out the company has a partnership with Apple in cardiac monitoring and with Sanofi (SNY) and Alphabet (GOOG) in diabetes. The analyst's guesses that its partnership is one element giving BioTelemetry management comfort in evaluating the role Apple might play in the company's future. O'Neil reaffirms a Buy rating on the shares with a $90 price target.

TODAY'S FREE FLY STORIES

TBPH

Theravance Biopharma

$27.53

-0.575 (-2.05%)

15:53
12/13/18
12/13
15:53
12/13/18
15:53
Recommendations
Theravance Biopharma analyst commentary  »

Piper Jaffray impressed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CC

Chemours

$27.13

0.47 (1.76%)

15:50
12/13/18
12/13
15:50
12/13/18
15:50
Options
Put spreads in Chemours Company as a position is adjusted »

Put spreads in Chemours…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,652.23

-11.17 (-0.67%)

, JNPR

Juniper

$28.18

-0.27 (-0.95%)

15:46
12/13/18
12/13
15:46
12/13/18
15:46
Periodicals
Amazon replacing some Juniper equipment with homegrown, Information says »

Hopes that Juniper (JNPR)…

AMZN

Amazon.com

$1,652.23

-11.17 (-0.67%)

JNPR

Juniper

$28.18

-0.27 (-0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

  • 20

    Dec

  • 29

    Jan

RH

RH

$129.68

-6.53 (-4.79%)

15:45
12/13/18
12/13
15:45
12/13/18
15:45
Options
Restoration Hardware call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBER

Uber

$0.00

(0.00%)

, SBUX

Starbucks

$66.72

0.62 (0.94%)

15:44
12/13/18
12/13
15:44
12/13/18
15:44
Hot Stocks
Starbucks expanding partnership with Uber Eats »

During Starbucks'…

UBER

Uber

$0.00

(0.00%)

SBUX

Starbucks

$66.72

0.62 (0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

KO

Coca-Cola

$49.47

0.27 (0.55%)

, KDP

Keurig Dr Pepper

$26.14

0.03 (0.11%)

15:37
12/13/18
12/13
15:37
12/13/18
15:37
On The Fly
UBS cuts Coca-Cola rating, says sell Monster Beverage »

As part of his initiation…

KO

Coca-Cola

$49.47

0.27 (0.55%)

KDP

Keurig Dr Pepper

$26.14

0.03 (0.11%)

TAP

Molson Coors

$63.21

0.2 (0.32%)

MNST

Monster Beverage

$53.51

-3.93 (-6.84%)

SAM

Boston Beer

$269.74

-4.34 (-1.58%)

FIZZ

National Beverage

$79.97

-4.15 (-4.93%)

PEP

PepsiCo

$118.31

1.33 (1.14%)

STZ

Constellation Brands

$183.03

-3.67 (-1.97%)

CCE

Coca-Cola European Partners

$0.00

(0.00%)

BFA

Brown-Forman, also tag with BF.A, BF.B

$0.00

(0.00%)

BFB

Brown-Forman, also tag with BF.A, BF.B

$0.00

(0.00%)

BF.A

Brown-Forman, also tag with BFA, BFB

$47.95

1.41 (3.03%)

BF.B

Brown-Forman, also tag with BFA, BFB

$47.43

0.95 (2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

  • 18

    Dec

  • 18

    Dec

  • 15

    Feb

  • 03

    Mar

SPY

SPDR S&P 500 ETF Trust

$264.81

-0.72 (-0.27%)

, SPX

S&P 500

$0.00

(0.00%)

15:22
12/13/18
12/13
15:22
12/13/18
15:22
Periodicals
Short interest in S&P 500 ETF 'jumps' to 5.3%, Bloomberg says »

Bloomberg, citing data…

SPY

SPDR S&P 500 ETF Trust

$264.81

-0.72 (-0.27%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DTEA

DavidsTea

$1.95

0.06 (3.17%)

15:19
12/13/18
12/13
15:19
12/13/18
15:19
Options
Davids Tea options imply 19.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
12/13/18
12/13
15:17
12/13/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
12/13/18
12/13
15:16
12/13/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$66.80

0.7 (1.06%)

15:11
12/13/18
12/13
15:11
12/13/18
15:11
Hot Stocks
Starbucks says starting new rewards program in China »

Starbucks executives…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

FFIN

First Financial

$60.53

-0.8 (-1.30%)

15:08
12/13/18
12/13
15:08
12/13/18
15:08
Hot Stocks
First Financial elects John Ruzicka Chief Information Officer »

First Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

RDNT

RadNet

$12.61

0.05 (0.40%)

15:08
12/13/18
12/13
15:08
12/13/18
15:08
Hot Stocks
RadNet and MemorialCare expand joint venture »

MemorialCare and RadNet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:05
12/13/18
12/13
15:05
12/13/18
15:05
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

SFLY

Shutterfly

$43.18

-1.65 (-3.68%)

15:04
12/13/18
12/13
15:04
12/13/18
15:04
Recommendations
Shutterfly analyst commentary  »

Shutterfly weakness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIIQ

Health Insurance Innovations

$35.90

5.835 (19.41%)

15:04
12/13/18
12/13
15:04
12/13/18
15:04
Recommendations
Health Insurance Innovations analyst commentary  »

Settlement should remove…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

COST

Costco

$225.93

-1.89 (-0.83%)

15:04
12/13/18
12/13
15:04
12/13/18
15:04
Options
Costco options imply 5.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HIIQ

Health Insurance Innovations

$35.90

5.835 (19.41%)

15:02
12/13/18
12/13
15:02
12/13/18
15:02
Recommendations
Health Insurance Innovations analyst commentary  »

Health Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

MRVL

Marvell

$15.53

0.18 (1.17%)

15:00
12/13/18
12/13
15:00
12/13/18
15:00
Options
Size time spread in Marvell Tech following an analyst upgrade »

Size time spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jan

  • 08

    Jan

G

Genpact

$28.14

-0.27 (-0.95%)

, EXLS

ExlService

$55.76

0.13 (0.23%)

14:57
12/13/18
12/13
14:57
12/13/18
14:57
Conference/Events
William Blair IT/BPO services analysts to hold analyst/industry conference call »

India IT/BPO Services…

G

Genpact

$28.14

-0.27 (-0.95%)

EXLS

ExlService

$55.76

0.13 (0.23%)

WNS

WNS Holdings

$46.99

-0.82 (-1.72%)

GLOB

Globant

$55.66

-1.37 (-2.40%)

PRFT

Perficient

$23.49

-0.28 (-1.18%)

VRTU

Virtusa

$41.05

1.2 (3.01%)

INFY

Infosys

$9.85

0.19 (1.97%)

WIT

Wipro

$5.30

0.19 (3.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$66.61

0.51 (0.77%)

14:56
12/13/18
12/13
14:56
12/13/18
14:56
Hot Stocks
Breaking Hot Stocks news story on Starbucks »

Starbucks says 80% of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

AAPL

Apple

$170.45

1.36 (0.80%)

, INTC

Intel

$48.11

0.28 (0.59%)

14:55
12/13/18
12/13
14:55
12/13/18
14:55
Recommendations
Apple, Intel analyst commentary  »

Lynx questions…

AAPL

Apple

$170.45

1.36 (0.80%)

INTC

Intel

$48.11

0.28 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

SBUX

Starbucks

$66.48

0.38 (0.57%)

14:50
12/13/18
12/13
14:50
12/13/18
14:50
Options
Heavy trading in Starbucks Weekly options during the company's Investor Day »

Heavy trading in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

ADBE

Adobe

$247.50

2.06 (0.84%)

14:49
12/13/18
12/13
14:49
12/13/18
14:49
Options
Adobe options imply 7.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

CMG

Chipotle

$472.11

0.91 (0.19%)

, DANOY

Danone

$0.00

(0.00%)

14:44
12/13/18
12/13
14:44
12/13/18
14:44
Hot Stocks
Chipotle announces hiring of Chief Legal Officer and Chief Development Officer »

Chipotle Mexican Grill…

CMG

Chipotle

$472.11

0.91 (0.19%)

DANOY

Danone

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 14

    Dec

  • 06

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.